1-4 of 4
Zhengping Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Low-Dose Immune Tolerance Induction Therapy for Severe Hemophilia a Inhibitor Patients: Immunosuppressants Improve Outcomes but Are Generally Not Necessary for Inhibitor-Titer below 200 BU/Ml

Zhengping Li, Man-Chiu Poon, Runhui Wu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3988.
https://doi.org/10.1182/blood-2023-184514
Published: 2023
Journal Articles

Chinese Severe Hemophilia a Children with High-Titer Inhibitors Obtain More Benefit from Intermediate-Dose Immune Tolerance Induction: The Interim Result of Lome Part a

Zhengping Li, Runhui Wu
Journal: Blood
Blood (2023) 142 (Supplement 1): 5478.
https://doi.org/10.1182/blood-2023-185290
Published: 2023
Journal Articles

Shorter Time Interval from Inhibitor Detection to Starting Low-Dose Immune Tolerance Induction Therapy Is Associated with Better Inhibitor Eradication Outcomes in Severe Hemophilia a Children with High-Titer Inhibitors in China

Zhengping Li, Man-Chiu Poon, Guoqing Liu, Zekun Li, Jie Sun, Runhui Wu
Journal: Blood
Blood (2022) 140 (Supplement 1): 2757–2758.
https://doi.org/10.1182/blood-2022-164999
Published: 2022
Journal Articles

Protocol and Primary Analysis of Lome: A Randomized Trial of Low- Versus Intermediate-Dose Immune Tolerance Induction with Recombinant Factor VIII (Omfiloctocog alfa, SCT800) in China

Zhengping Li, Guoqing Liu, Zhen Yingzi, Xiaoling Cheng, Zhenping Chen, Di Ai, Zekun Li, Jie Sun, Kun Huang, Sr., Runhui Wu
Journal: Blood
Blood (2022) 140 (Supplement 1): 5615–5616.
https://doi.org/10.1182/blood-2022-164951
Published: 2022